Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Gene Editing
First in vivo CRISPR gene editing in humans
by Ryan Cross
March 7, 2020
| A version of this story appeared in
Volume 98, Issue 9
Editas Medicine and Allergan have begun a clinical trial of a CRISPR gene-editing therapy designed to remove a genetic mutation that causes a rare form of inherited blindness. The therapy, which is packaged in a virus, is injected under the retina of the eye during surgery. While other groups have used CRISPR on blood and immune cells removed from the body, the trial by Editas and Allergan marks the first time CRISPR has been used directly inside the body, a feat called in vivo gene editing.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter